Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | TET3 | O43151 | 1/20 | 0.53 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.53 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.53 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.53 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13774957 | 0.90 | CA12 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL23779147 | 0.86 | KMT2A (0.69) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL8324812 | 0.84 | OPRM1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3543988 | 0.84 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18068774 | 0.84 | OPRM1 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL890180 | 0.83 | AKR1C1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5172596 | 0.83 | KMT2A (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1309812 | 0.82 | SLC18A3 (0.60) | KMT2ATET3FBXL19CXXC5TET1 | |
| SCHEMBL6032506 | 0.82 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8162122 | 0.81 | CA12 (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | CA12 2612/4885CA1 1664/4885CA2 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.